



(11) Publication number:

**0 392 745
A2**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90303681.2

(51) Int. Cl.⁵: **A61K 47/48, A61K 37/54,
C07D 501/00, C07D 499/00**

(22) Date of filing: 05.04.90

(30) Priority: 05.04.89 GB 8907617

(43) Date of publication of application:
17.10.90 Bulletin 90/42

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant: **CELLTECH LIMITED**
216 Bath Road
Slough Berkshire SL1 4EN(GB)

(72) Inventor: **Eaton, Michael Anthony William**
Nethercote, Chinnor Road
Aston Rowant, Oxfordshire OX9 5SH(GB)
Inventor: **Pratt, Andrew John**
Jesus College
Oxford OX1 3DW(GB)
Inventor: **Alexander, Rikki Peter**
2 Warwick Avenue
High Wycombe, Buckinghamshire PH12
4NG(GB)

(74) Representative: **Hallybone, Huw George et al**
CARPMAELS AND RANSFORD 43
Bloomsbury Square
London WC1A 2RA(GB)

(54) **Immunoconjugates and prodrugs and their use in association for drug delivery.**

(57) A drug delivery system is described in which an immunoconjugate and a prodrug are used in association with each other to deliver a drug to a host target site such as a tumour. The immunoconjugate comprises an antibody or antibody fragment to which is attached a β -lactamase or an active fragment thereof. The prodrug is a cyclic amide derivative of a drug or an unstable precursor thereof in which the drug or precursor is attached to the remainder of the prodrug such that it forms a leaving group which on hydrolysis of the prodrug is eliminated as the active drug or unstable precursor. Particular prodrugs include penicillin or cephalosporin derivatives and other β -lactams to which are attached any physiologically active substances, particularly antineoplastic agents, antiviral, antibacterial or antifungal compounds. In use the immunoconjugate is administered first such that it localises at the host target site. Subsequent administration of the prodrug results in β -lactamase catalysed hydrolysis of the prodrug at the target site with release of the active drug or unstable precursor.

EP 0 392 745 A2

Immunoconjugates and prodrugs and their use in association for drug delivery

Field of the Invention

This invention relates to a system for the targetted delivery of drugs to humans. More particularly, it relates to immunoconjugates, to prodrugs, and to their use in association for the targetted delivery of drugs to humans.

Background to the Invention

There are numerous drugs available, for example for the treatment of cancer, which can not be effectively utilised by standard systemic administration because of toxic effects to the normal tissues of the host. In such instances, the success of any treatment with the drug will depend to a large extent on the ability to selectively target it to the diseased tissue. Unfortunately, many previous attempts to target drugs specifically have failed because of the lack of qualitative and quantitative biochemical differences between normal and diseased tissue.

The advent of monoclonal antibody technology, however, has provided a means for selective targetting of tissues. Thus, by coupling or complexing an antibody with a drug in such a way that the resulting immunoconjugate retains the antigenic binding properties of the antibody and activity of the drug, it is possible to direct and convey the drug to a selected tissue.

The success of this approach depends on achieving an effectively high concentration of the drug containing immunoconjugate at the disease site and maintaining this concentration for a sufficient length of time for the drug to exert the desired therapeutic effect. In practice this has proved to be a significant problem, since in most cases reported to date very little of the immunoconjugate dose is found to localise at the desired site, resulting in relatively low levels of delivery of the drug.

It is undesirable from both a clinical and economic point of view to offset this difficulty by increasing the dose of immunoconjugate. Increasing dosage may increase side effects in the patient such as immune response and non specific toxicity. A requirement for large amounts of immunoconjugate is also undesirable because of its high cost of production. Similarly, increasing the toxicity of the drug attached to the antibody to offset this difficulty is also likely to increase toxic side effects on normal tissue. There has therefore been a need to improve monoclonal antibody based drug targetting methods such that the delivered dose of drug is increased without radical increase in the applied dose of immunoconjugate.

One recently suggested method for overcoming this problem employs a monoclonal antibody-enzyme-prodrug system, described more particularly in European Patent Applications Nos. 86100130.3 (Publication number 0 187 658) and 88112646.0 and International Patent Application No. PCT/GB 88/00181.

In a particular example of the method, a monoclonal antibody or antibody fragment specific for a tumour associated antigen (i.e. an antigen present in relatively high levels on the surface of or within tumour cells compared with normal cells where it may also be present) is linked to an enzyme using chemical cross-linking, or recombinant DNA gene fusion and expression techniques. The linkage is achieved in such a manner that the resulting immunoconjugate retains both the antigen recognition ability of the antibody and the catalytic activity of the enzyme. A substrate for the enzyme is synthesised which consists of a tumouricidal drug in an innocuous non-tumouricidal form (termed a prodrug). The prodrug is converted into the tumouricidal drug form by the action of the enzyme.

In order to achieve an antitumour effect the immunoconjugate is first injected or infused into the patient and allowed to localise at the site of the tumour. A period of time is allowed to elapse in which non-tumour bound immunoconjugate is allowed to largely clear from the patient by metabolism and excretion. The prodrug is then injected or infused. Upon reaching the tumour, the prodrug is converted to drug by the enzyme portion of the bound immunoconjugate. The dose of prodrug given will be that required to generate a therapeutically effective concentration of the drug at the site of the tumour. The *de novo* created drug then exerts its tumouricidal effect in the immediate vicinity of the tumour thus tending to minimise exposure of normal tissue to its effects. The clearance period after infusion of the immunoconjugate is aimed at minimising the level of immunoconjugate in non-tumour tissue. This is required to limit generation of drug from prodrug by the enzyme portion of the immunoconjugate in non-tumour tissue. Treatment is halted by the termination of infusion of the prodrug.

The method thus rests on an enzyme-mediated drug amplification effect in which the number of toxic molecules is greatly increased over the number of immunoconjugate molecules at the site of the tumour.

This achieves an effective local increase in concentration of the drug without the need to resort to an increase in dose of the immunoconjugate.

Particular antibody-enzyme-prodrug systems of the above type which have been described include those in which urokinase, (European Patent Application No. 86100130.3) carboxypeptidase G₂, [International Patent Application No. PCT/GB 88/00181; Bagshaw *et al*, Br. J. Cancer **58**, 700 - 703, (1988)] or alkaline phosphatase penicillin V amidase and cytosine deaminase, [European Patent Application No. 88112646.0; Senter *et al* PNAS (1988), **85**, 4842-4846] have been coupled to antibodies for use with plasminogen, benzoic acid mustard, etoposide phosphate, N-(p-hydroxyphenoxyacetyl)adriamycin or 5-fluorocytosine prodrugs, respectively.

10

Summary of the Invention

The present invention concerns an antibody-enzyme-prodrug delivery system of the above general type, but wherein active drug is generated from inactive prodrug at the host target site by the action of a β -lactamase enzyme conveyed there by an appropriate antibody. European Patent Application No. 88112646.0 mentions the possibility of using *inter alia* antibody- β -lactamase conjugates with, generally, drugs derivatised with β -lactams.

It will be appreciated that β -lactamases are capable of hydrolysing a wide range of β -lactam substrates. In certain substrates, hydrolysis is also accompanied by elimination of a leaving group. In the present invention, we have designed substrates for β -lactamases in which use is made of this mechanism to provide a means for generating active drug from inactive drug.

Thus according to one aspect of the invention we provide a system for delivering a drug at a host target site, the system comprising an immunoconjugate and a prodrug for use in association with each other, said immunoconjugate being capable of recognising and binding to one or more epitopes associated with the host target site and having a β -lactamase action capable of hydrolysing said prodrug to active drug or an unstable precursor thereof at the target site, characterised in that said prodrug comprises a cyclic amide derivative of a drug or an unstable precursor thereof wherein the drug or unstable precursor thereof is linked to the remainder of the prodrug such that it forms a leaving group which on hydrolysis of the prodrug is eliminated as the active drug or an unstable precursor thereof.

The term epitope as used herein is intended to mean any immunogenic site to which an antibody may recognise and bind.

The system according to the invention may be used for delivering a drug at any host target site where treatment is required, providing the target site has one or more epitopes that are substantially unique to that site, and which can be recognised and bound by the immunoconjugate. Particular target sites include those regions in a host arising from a pathogenic state induced by, for example a tumour, a bacterium, a fungus or a virus; or as a result of a malfunction of a normal host system, for example in cardiovascular diseases, such as the formation of the thrombus, in inflammatory diseases, and in diseases of the central nervous system.

In the delivery system according to the invention, the immunoconjugate may in general comprise at least an antigen binding domain of an antibody and at least the active portion of a β -lactamase covalently linked such that each is separately functional. Thus, the immunoconjugate may be a whole antibody or an antigen binding fragment thereof, covalently linked to a β -lactamase enzyme or an active fragment thereof.

The antibody or antibody fragment may in general belong to any immunoglobulin class. Thus, for example, it may be an immunoglobulin M antibody or, in particular, an immunoglobulin G antibody. The antibody or fragment may be of animal, for example mammalian origin and may be for example of murine, rat or human origin. It may be a natural antibody or a fragment thereof, or, if desired, a recombinant antibody or antibody fragment, i.e. an antibody or antibody fragment which has been produced using recombinant DNA techniques.

Particular recombinant antibodies or antibody fragments include, (1) those having an antigen binding site at least part of which is derived from a different antibody, for example those in which the hypervariable or complementarity determining regions of one antibody have been grafted into the variable framework regions of a second, different antibody (as described in European Patent Specification No. 239400); (2) recombinant antibodies or fragments wherein non-Fv sequences have been substituted by non-Fv sequences from other, different antibodies (as described in European Patent Specifications Nos. 171496, 173494 and 194276); or (3) recombinant antibodies or fragments possessing substantially the structure of a natural immunoglobulin but wherein the hinge region is a different number of cysteine residues from that found in the natural immunoglobulin, or wherein one or more cysteine residues in a surface pocket of the

recombinant antibody or fragment is in the place of another amino acid residue present in the natural immunoglobulin (as described in International Patent Applications Nos. PCT/GB 88/00730 and PCT/GB 88/00729 respectively).

The antibody or antibody fragment may be of polyclonal, or, preferably, monoclonal origin. It may be specific for a number of epitopes associated with the host target site, but is preferably specific for one.

Antigen binding antibody fragments include for example fragments derived by proteolytic cleavage of a whole antibody, such as $F(ab')_2$, Fab' or Fab fragments, or fragments obtained by recombinant DNA techniques, for example Fv fragments (as described in International Patent Application No. PCT/GB/88/00747). Other fragments include peptides related to the so-called complementarily determining region of antibodies which may possess the ability to bind antigen.

The β -lactamase to which the antibody or antibody fragment is linked to form the immunoconjugate may in general be a β -lactamase (EC 3.5.2.6) from any prokaryotic source. Typical sources include *Eschericia*, *Staphylococci*, *Pseudomonas*, *Bacteriodes*, *Klebsiella*, *Citrobacter*, *Bacillus*, *Enterobacter*, and *Streptococci*. Particular β -lactamases include those found in *B. cereus*, *Enterobacter cloacae* and *E. coli*, especially *E. Coli* R-TEM. Fragments of β -lactamases may also be used, for example proteolytic fragments, or fragments produced by expression of a truncated or modified form produced by recombinant DNA technology, providing enzyme activity is retained.


The β -lactamase or fragment thereof may be linked to the antibody or antibody fragment either directly, or indirectly through a linker group, to form the immunoconjugate for use in the invention. Direct linkage is to be understood to mean peptide bond formation between the C-terminal amino acid of a heavy or light chain of the antibody or fragment and the N-terminal amino acid of the β -lactamase or fragment thereof. Indirect linkage is to be understood to mean linkage of the antibody and enzyme, or fragments thereof, by a synthetic bridging group covalently coupling amino acid side chains, or derivatives thereof, in the antibody and enzyme. Suitable bridging groups include for example optionally substituted bivalent radicals of aliphatic, aromatic or araliphatic compounds. Particular examples include those described by Ghose, T. I. et al in *Methods in Enzymology* (1983), 93, 280-333.

The prodrug for use in the delivery system according to the invention in general may be any inactive form of a drug from which the active form or an unstable precursor may be generated by the action of a β -lactamase at the target site.

The prodrug may thus be for example a compound of partial formula (1)




wherein -A is a group



and X is a hydrogen atom or an organic group, [for example an aliphatic, heteroaliphatic, aromatic, heteroaromatic, carboxylic, amino or nitrile group] and L is a drug or an unstable precursor thereof linked to the remainder of the molecule such that it forms a leaving group.


The prodrug may thus be for example a compound of partial formula (2)




wherein L is as just defined.

Particular groups of compounds of formula (1) include cephalosporin and penicillin derivatives of formula (3):

15



30 (wherein R is an acyl or alkyl radical; R¹ is a hydrogen atom or an alkoxy group; B is -CH₂-, -O-, or -S- and n is zero or an integer 1 to 4 inclusive; and L is as just defined); and monobactams of formula (4):



(wherein R, R¹ and L are as just defined).

In the above compounds the acyl group represented by the group R may be for example any acyl group known from the penicillin and cephalosporin art. Thus R may be for example an optionally substituted aliphatic, heteroaliphatic, aromatic, heteroaromatic, araliphatic, or heteroaraliphatic carboxylic or carbothioic acid radical or a carbamyl radical.

50

One particular group of acyl groups represented by R are those of formula R²C=X, where X is an oxygen or sulphur atom and R² represents a hydrogen atom or a group selected from amino, substituted amino e.g. -NR³R⁴ (where R³ and R⁴ which may be the same or different is each a hydrogen atom or a C₁₋₆ alkyl group), C₁₋₆ alkyl, C₁₋₆ alkythio, C₆₋₁₂ arylthio, C₁₋₆ alkoxy, C₂₋₆ alkenyl or alkynyl, aryl, e.g. phenyl, arC₁₋₃alkyl, e.g. benzyl, C₃₋₆ cycloalkyl, C₄₋₁₀ heteroaryl or heteroarC₁₋₃alkyl where the heteroatom or atoms are selected from O, N or S, e.g. thienyl or thienylmethyl. Each of the above groups may be optionally substituted by further atoms or groups, for example by halogen atoms, e.g. chlorine atoms, or by

55

groups such as -OH, -SR⁵ (where R⁵ is a hydrogen atom or an alkyl or aryl group), C₁-₆alkyl, C₁-₆alkoxy, cyano, carboxy, sulphamino, carbam yl, suphonyl, azido, amino, substituted amino (as defined above) haloC₁-₆ alkyl, e.g. trifluoromethyl, carboxyC₁-₆alkyl carbamoylC₁-₆alkyl, N-carbamoylC₁-₆alkyl, amidino, guanidino and substituted guanidino.

5 When R is an alkyl group it may be for example a straight or branched C₁-₆alkyl group, e.g. methyl, ethyl, n-propyl, n-pentyl or n-hexyl group.

It will be appreciated that the group R may be varied widely without affecting the usefulness of the delivery system according to the invention. One group R however which we have found to be particularly useful is 2-thienylacetyl.

10 The group R¹ in the above compounds may be a C₁-₆alkoxy e.g. methoxy group, but is preferably a hydrogen atom.

In the above compounds, β -lactamase hydrolysis of the cyclic amide also results in liberation of the drug or unstable precursor, providing either is linked to the remainder of the molecule in such a manner that it forms a leaving group. Thus, the linkage will generally be through an oxygen, nitrogen or sulphur atom present in the drug. Particular examples of L include -O-CO-L¹, and -S-L¹ where L¹ is the remainder of the drug or unstable precursor. Preferred linkages are those that are not susceptible to cleavage by host enzyme mechanisms (e.g. esters may be cleaved by host esterases), to avoid premature release of the drug at sites other than the target site.

The term unstable precursor as used herein in relation to a drug is intended to mean a metabolically or inherently unstable precursor of the drug. Metabolically unstable precursors of the drug are those from which active drug may be generated by host cell mechanisms at the host target site. Inherently unstable precursors of the drug are those which spontaneously decompose to active drug at the host target site. Particular examples include carbonate, thiocarbonate, carbamate and thiocarbamate derivatives of the drug.

The term drug as used herein is intended to mean any physiologically active substance, antibacterial, 25 antiviral or antifungal compound. Particular physiologically active substances include antineoplastic agents, including cytotoxic and cytostatic agents, hormones, anti-inflammatory compounds, and substances active as cardiovascular, e.g. fibrinolytic, and central nervous system agents.

The delivery system according to the invention is particularly useful for targeting drugs to tumours and in a preferred aspect the invention thus provides a system for delivering a drug to a tumour, the system 30 comprising an immunoconjugate and a prodrug for use in association with each other, said immunoconjugate being capable of recognising and binding to one or more tumour associated epitopes and having a β -lactamase action capable of hydrolysing said prodrug to active drug or an unstable precursor thereof at the tumour site, characterised in that said prodrug comprises a cyclic amide derivative of a drug or an unstable precursor thereof wherein the drug or an unstable precursor thereof is linked to the remainder of the such that it forms a leaving group which on hydrolysis of the prodrug is eliminated as the active group 35 or an unstable precursor thereof.

According to this aspect of the invention, the immunoconjugate may generally be as described previously, providing it is capable of binding to at least one tumour associated epitope. Particular epitopes include oncofetal antigens such as carcinoembryonic antigen or alphafetoprotein, placental antigens such as 40 chorionic gonadotropin and placental alkaline phosphatase, and prostate antigens such as prostatic acid phosphatase and prostate specific antigen.

Immunoconjugates capable of recognising and binding one or more epitopes on the TAG-72 antigen associated with human breast and colon tumours are particularly useful in delivery systems according to this aspect of the invention. Particularly preferred immunoconjugates of this type are those wherein the 45 monoclonal antibody B72.3 [Colcher, D. et al Proc. Nat. Acad. Sci. USA (1981), 78, 3199] or a fragment thereof or a recombinant B72.3 antibody or fragment thereof is covalently linked to a β -lactamase. Recombinant B72.3 antibodies or fragments include those of the type described above in relation to antibodies generally.

Suitable prodrugs for use in this aspect of the invention include inactive forms of antineoplastic drugs 50 from which the active form or an unstable precursor may be generated by the action of a β -lactamase. Thus the prodrug may be a cyclic amide derivative of an antineoplastic agent, for example a compound of partial formulae (1), or (2) or of formulae (3) or (4) wherein L is an antineoplastic agent or an unstable precursor thereof linked to the remainder of the molecule such that it forms a leaving group.

Particular antineoplastic agents include cytotoxic and cytostatic agents, for example alkylating agents, 55 such as nitrogen mustards (e.g. chlorambucil, melphalan, mechlorethamine, cyclophosphamide, or uracil mustard) and derivatives thereof, triethylenephosphoramid, triethylenethiophosphoramid, busulphan, or cisplatin; antimetabolites, such as methotrexate, fluorouracil and floxuridine, cytarabine, mercaptopurine, thioguanine, fluoroacetic acid or fluorocitric acid; antibiotics, such as bleomycins (e.g. bleomycin sulphate),

doxorubicin, daunorubicin, mitomycins (e.g. mitomycin C), antinomycins (e.g. dactinomycin) plicamycin, calicheamicin, or esperamicin; mitotic inhibitors, such as etoposide, vincristine or vinblastine and derivatives thereof; alkaloids, such as ellipticine; polyols such as taxixin-I or taxicin-II; hormones, such as androgens (e.g. dromostanolone or testolactone), progestins (e.g. megestrol acetate or medroxyprogesterone acetate),
 5 estrogens (e.g. diethylstilbestrol diphosphate, polyestradiol phosphate or estramustine phosphate) or antiestrogens (e.g. tamoxifen); ureas, such as hydroxyurea; hydrazines, such as procarbazine; or imidazoles, such as dacarbazine.

Particularly useful prodrugs for use in delivery systems according to this aspect of the invention are those of formula (3) wherein R, R', B and n are as defined for formula (3) and L is a group -OCOL' where
 10 L' is a group -NR⁶R⁷ wherein R⁶ and R⁷ which may be the same or different is each a hydrogen atom or an optionally substituted C₁₋₆alkyl [e.g. ethyl or propyl] or nitroso group, with the proviso that only one of R⁶ or R⁷ is a hydrogen atom; or a group -P-NR⁶R⁷ where P is a phenyl group. Examples of the substituents which may be present on R⁶ and R⁷ alkyl groups include halogen atoms, e.g. chlorine or bromine atoms.

15 Another important group of compounds of formula (3) are those wherein L is a mercaptopurine or thioguanine group.

Compounds of formula (3) in which L is an antineoplastic agent as defined above, R and R' are as defined for formula (3), especially where R' is a hydrogen atom, B is -S- and n is an integer 1 are particularly important. Compounds of this type in which L is a group -OCOL' as just defined or a
 20 mercaptopurine or thioguanine group are especially useful.

Compounds of the above specific types form a further feature of the invention.

The efficacy of a system according to the invention may be initially determined using appropriate model in vitro or in vivo test systems, for example by use of in vitro cell killing systems as described by Phillips (1974), *Biochem. Pharmacol.* 23, 131-138 or a mouse xenograft model as described by Searle et al (1981).
 25 in *Br.J.Cancer* 44, 137-144, and Bagshawe et al (1988) in *Br.J.Cancer* 58, 700-703.

The system according to the invention may be used in humans as generally described previously. Thus, the immunoconjugate will be administered first, and a period of time then allowed to elapse before the prodrug is administered. The period of time between the end of administration of the immunoconjugate and the beginning of administration of prodrug will vary depending on the site to be targetted and the
 30 nature of the immunoconjugate and prodrug, together with other factors such as the age and condition of the patient. Thus the exact regime will usually need to be determined empirically, with the aim of achieving a maximal concentration of immunoconjugate at the target site and a minimal concentration elsewhere in the patient, before the prodrug is administered. In this way, an optimum selective therapeutic effect can be achieved.

35 In practice, it may be desirable to space apart administration of immunoconjugate and prodrug by at least 4 hours. More than one administration of prodrug may be necessary to achieve the desired therapeutic effect.

The immunoconjugate and prodrug may be administered by any suitable route, preferably parenterally, e.g. by injection or infusion. Suitable formulations of the immunoconjugate or prodrug for parenteral
 40 administration include suspensions, solutions or emulsions of each component in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the immunoconjugate or prodrug may be in powder form for reconstitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use. If desired, the immunoconjugate and/or prodrug may be presented in unit dosage form.

45 The precise doses at which the immunoconjugate and prodrug will be administered will depend on the route of administration, body weight and pathology of the patient, the nature of the prodrug, and the catalytic properties of the β -lactamase. Thus, for example, the immunoconjugate may be administered at doses in the range 100 to 2000 U/kg. The prodrug may be administered at doses in general use for the administration of the drug itself, but will preferably be administered at lower doses, for example, or around
 50 0.001 to 0.5 times the normally administered dose of drug alone.

Immunoconjugates for use in the delivery system according to the invention may be prepared by linking an antibody or antibody fragment to a β -lactamase or a fragment thereof either by recombinant DNA technology, or by conventional chemical cross-linking.

Standard recombinant DNA techniques may be used. Thus, the DNA encoding the heavy (H) chain of
 55 an antibody (or a fragment of the H chain bearing the antigen combining site) may be ligated to the DNA sequence encoding the β -lactamase or fragment thereof. The resulting H chain-enzyme hybrid may then be expressed and secreted from transformed mammalian or microbial cells in culture together with the appropriate light (L) chain (or L chain fragment). The expressed antibody H chain-enzyme hybrid associates

with the expressed L chain to form a functional Fv, Fab or full length HL antibody half molecule depending on the portion of the H chain chosen for expression. Conversion of the resulting monomeric HL species into dimers via cross linking at sulphhydryl residues located in the hinge antibody region if present may occur spontaneously by air oxidation during cell culture, or may be achieved using appropriate oxidising agents or by reaction with chemical cross-linkers.

Alternatively, the DNA of the light chain of the antibody (or fragment) may be ligated to the β -lactamase or a fragment thereof. The resulting hybrid may be expressed with the appropriate H chain as described above.


Where it is desired to link the antibody and β -lactamase by chemical means, conventional cross-linking reagents may be used, for example, as described by Ghose T. I. et al (ibid). Thus, for example, the antibody or antibody fragment may be joined to the enzyme or fragment thereof using a heterobifunctional linking reagent of formula X-Z-Y (where X and Y, which are different, is each a reactive functional group, and Z is a spacer group). In the linking reagent, X and Y may be chosen such that for example one is a thiol-reactive functional group and the other an amino reactive functional group capable of reacting with an appropriate group in the antibody or enzyme. Particular examples include succinimidyl pyridyl dithiopropionate, 4-(N-maleimidomethyl) cyclohexane-1-carboxylic acid, N-hydroxysuccinimide ester, and 3-maleimidobenzoyl-N-hydroxysuccinimide ester. Addition of the linking reagent to either the antibody or enzyme under conditions favouring reaction of only one of the groups X or Y yields an antibody or enzyme derivative which may be further reacted (after removal of excess reagent X-Z-Y, e.g. by gel filtration or dialysis) with the remaining antibody or enzyme component to yield the desired immunoconjugate. Separation of the immunoconjugate from the reaction mixture may then be achieved using conventional protein purification techniques.

Alternatively, homobifunctional reagents in the form X-Z-X e.g. dimethylsuberimidate may be employed which introduce intermolecular cross-links between antibody and enzyme in a single step via identical amino acid side-chains (e.g. lysine residues). Once formed, the immunoconjugate may be separated and purified using conventional protein purification techniques.

Antibodies or antibody fragments may be obtained by conventional means, for example from the sera of immunised animals, or, preferably, myeloma or hybridoma cells, or by recombinant DNA techniques as described in European Patent Specifications 171496, 173494, 194276 and 239400, and International Patent Applications Nos. PCT/GB 88/00729 and PCT/GB 88/00730. If desired, the antibody may be modified prior to reaction with the linking reagent, to introduce reactive groups, e.g. free thiol groups may be generated in the antibody by reaction with a thiolating reagent such as 2-iminothiolane.


β -Lactamases for use in the immunoconjugates are either widely available or may be obtained from known sources using standard techniques. The degree of suitability of any particular β -lactamase for use in the invention may be determined before or after conjugation to antibody using small scale screening tests, for example by determining the *in vitro* hydrolysis of a prodrug by the enzyme as described in more detail below.

Prodrugs for use in the delivery system according to the invention may be prepared by reaction of the drug or a metabolically unstable precursor thereof with a suitably activated cyclic amide derivative. In the following description reference is made to the preparation of compounds of formula (3) for convenience, but the processes described may be used for the preparation of any compound of partial formula (1) where A is a group



or partial formula (2) or formula (4).

Thus, a compound of formula (3) may be prepared by reaction of a compound of formula (5):



15 [wherein W is a reactive group such as a -CHO, -OH, -OR^a (where R^a is a sulphonyl group such as a methanesulphonyl or p-toluenesulphonyl group), Hal (where Hal is a halogen atom such as a chlorine or iodine atom), -NH₂, -OCONH₂ or -OCOCH₃ group] with a drug or metabolically unstable precursor thereof under conditions such that either nucleophilic displacement of, or electrophilic addition to, the group W is achieved via a suitable reactive group [for example a thiol, isocyanate, carboxyl, activated carboxyl, or

20 hydroxyl group] in the drug or precursor. The reaction may be effected in an aqueous or organic solvent, for example a halogenated hydrocarbon, e.g. dichloromethane or a substituted amide, e.g. dimethylformamide using standard conditions for example in the presence of a base such as pyridine.

Alternatively, if desired, a compound of formula (3) may be prepared from a compound of formula (5) in a multi-stage reaction wherein the drug or an unstable precursor thereof is synthesised in step-wise fashion

25 on the cyclic amide nucleus. Thus, for example, a compound of formula (5) wherein W is a hydroxyl group may be reacted with an acid (R^bCOOH) or an activated derivative thereof (e.g. an acid halide or anhydride) to yield an intermediate compound wherein W is a group -OCOR^b. The reaction may be performed under standard conditions, for example in an aqueous or organic solvent, for example an ether such as tetrahydrofuran, where necessary in the presence of an acid or base, e.g. an organic amine such as

30 pyridine. By appropriate initial choice of the group R^b such that it forms a good leaving group (e.g. a p-nitrophenoxy or pentafluorophenoxy group) the intermediate may be subsequently reacted with a drug or a precursor thereof (for example as described above) to yield the desired compound of formula (3).

Where a precursor of the drug is used this may be subsequently converted to the drug using standard reactions and conditions, for example as described in the following Examples. Thus for example where

35 the drug contains a halogen atom this may be introduced in a final step by reaction of a corresponding compound containing a hydroxyl group with a sulphonyl chloride (e.g. methanesulphonyl chloride) in a base such as pyridine followed by reaction with a N-haloimide e.g. N-chlorosuccinimide. Alternatively chlorine and bromine atoms may be interconverted in a final step for example by treatment of a chlorine containing drug with a bromophosphorane e.g. dibromotriphenylphosphorane in the presence of a base such a

40 pyridine. In another example, N-nitroso groups may be introduced in a final step by reaction of a corresponding secondary amine with N₂O₄.

It will be appreciated that in reactions of the above kind, it may be desirable to protect other reactive groups, for example carboxylic acid groups, in the cyclic amide or drug to avoid the possibility of side reactions occurring. Conventional protection procedures may be used, (for example carboxylic acids may


45 be protected as esters e.g. diphenylmethyl esters) such that the protecting group may be conveniently removed without affecting the remainder of the molecule once the desired reaction has been effected.

In the above synthetic procedures we have found that compounds of formula (5) wherein W is a group -OCOOW¹ where W¹ is a fluorophenyl group, especially a pentafluorophenyl group, are particularly useful intermediates. Such compounds are new and form a further aspect of the invention.

50 Where the intermediate compounds of formula (5) are cephalosporin or penicillin derivative, these may be obtained by conventional methods from known starting materials, for example as described by C. F. Murphy and J. A. Webber, in "Cephalosporins and Penicillins: Chemistry and Biology", ed. E. H. Flynn, pp 134-182, Academic Press 1972. Other cyclic amides of formula (5) together with starting materials for use in the preparation of compounds of formula (3) and other compounds of partial formula (1) may be prepared


55 from known starting materials using analogous methods to those used for the preparation of the cephalosporin derivatives.

Compounds of partial formula (1) wherein A is a group



5

may be prepared by alkylation of a corresponding compound wherein A is a group



10

using a reagent YCH_2L where Y is a reactive group such as a halogen atom, using standard conditions.

15

The following Intermediates and Examples illustrate the preparation of prodrugs and antibody- β -lactamase conjugates for use according to the invention.

20 Description of Specific Embodiments

Intermediate 1

25

3-Hydroxymethyl-7 β -(2-thienylacetamido)-3-cephem-4-carboxylic Acid

To a solution of cephalothin sodium salt (12.2g) in water (60ml) at 0°C was added in one portion, 20% NaOH solution (120ml) was previously cooled in a dry ice/acetone bath to -20°C. The temperature immediately increased to -4°C and was then reduced to -10°C. The mixture was agitated by hand for 135s, including cooling period. Upon rapidly quenching the reaction with glacial acetic acid (39ml) the temperature increased to +15°C. After recooling to +10°C, concentrated hydrochloric acid (70ml), precooled to 0°C, was added until the acid just precipitated (pH=1.5). The resulting acid was washed twice with cold water and dried in vacuo overnight, to yield the title compound (7.4g)

m.p.: 214-215°C (dec.); I.R. ν_{max} (Nujol): 3500 (alcohol), 3280, 2900, 1760 (β -lactam), 1715, 1640 (amide) cm^{-1} ; ^1H nmr δ_{H} (D_2O , NaHCO_3): 3.25 and 3.45 (2H, ABq, J 17.8 Hz, C-2H₂), 3.70 and 3.77 (2H, ABq, J 15.8 Hz, C-7CH₂), 4.06 and 4.11 (2H, ABq, J 12.9 Hz, C-3CH₂), 4.93 (1H, d, J 4.7 Hz, C-6H), 5.44 (1H, d, J 4.7 Hz, C-7H), 6.87-6.89 (2H, m, 2 thiophene H) and 7.19-7.21 (1H, m, thiophene H).

40

Intermediate 2

Diphenylmethyl 3-Hydroxymethyl-7 β -(2-thienylacetamido)-3-cephem-4-carboxylate

45

To deacetyl cephalothin (14.8g) in acetone (150ml) was added a solution of diphenyl diazomethane (9.7g) in acetone (100ml). The mixture was stirred at room temperature under nitrogen for 40 min. The product was precipitated with hexane (150ml), filtered, washed with hexane, and dried in vacuo, to yield the title compound (13.1g), I.R. ν_{max} (CHCl_3): 3400, 3010, 1790 (β -lactam), 1710 (ester), 1685 (amide) cm^{-1} ; ^1H nmr δ_{H} (CDCl_3): 3.55 (2H, s, C-7CH₂), 3.94 and 4.40 (2H, BAq, J 12.9 Hz, C-2H₂), 4.94 (1H, d, J 4.9 Hz, C-6H), 5.90 (1H, dd, J 4.9 and 9.2 Hz, C-7H), 6.44 (1H, d, J 9.2 Hz, C-7NH), 6.91 (1H, s, C-4CH), 6.97-7.02 (2H, m, 2 thiophene) and 6.97-7.02 (11H, m, 11 thiophene and phenyl H); MS (FD): m/z 520 (M^+)

50

Intermediate 3

55

Diphenylmethyl 3-Pentafluorophenoxycarbonylmethyl-7 β -(2-thienylacetamide)-3-cephem-4-carboxylate.

To a stirred solution of phosgene (2.07 ml of a 1.93M solution) in dry tetrahydrofuran (THF) (10 ml) at 0°C was added pyridine (0.323ml) followed by pentafluoro phenol (0.736g) as a solution in THF (4ml). The mixture was stirred at 0°C for 30 minutes and then Intermediate 2 (2.08g) and pyridine (0.323ml) added together as a solution in THF (5ml) dropwise. The reaction mixture was stirred at 0°C for 30 minutes and then at room temperature for 1 hour then poured into saturated NaHCO₃ solution (150ml) and extracted twice with CH₂Cl₂ (150ml). The combined organic fractions were dried over MgSO₄, filtered and the solvent removed by evaporation in vacuo to yield the title compound (2.61g) I.R. ν_{max} (KBr): 2970, 1778 (β -lactam), 1728 (ester), 1692 (carbonate), 1680 (amide) cm⁻¹; ¹H nmr_δH (CDCl₃): 3.42 and 3.61 (2H, ABq, J 18.75 Hz, C-2H₂), 3.85 (2H, s, C-7CH₂), 5.01 and 5.35 (2H, ABq, J 15 Hz, C-3CH₂), 5.0 (1H, d, J 6 Hz, C-6H), 5.90 (1H, dd, J 6 and 8.25 Hz, C-7H), 6.74 (1H, d, J 8.25 Hz, C-7NH), 6.88 (1H, s, C-4CH), 6.90-7.00 (2H, m, 2H thiophene), and 7.18-7.25 (13H, m, 11 thiophene and phenyl, H).

Intermediate 4

Diphenylmethyl 3-(bis-2-hydroxyethyl carbamoyl)-7 β -(2-acetamido)-3-cephem-4-carboxylate

To a stirred solution of Intermediate 3 in dry pyridine (10ml) at 0°C was added diethanolamine (0.32g) as a solution in pyridine (5ml). The mixture was stirred for 2 hrs. The solvent was removed by evaporation in vacuo, the residue dissolved in CH₂Cl₂ (100ml) and washed with saturated NaHCO₃ solution (100ml). The organic layer was dried over MgSO₄, filtered and the solvent removed by evaporation in vacuo. Purification was by column chromatography eluting with ethyl acetate to yield the title compound (0.3g) ¹H n.m.r._δH - (CDCl₃): 3.32-3.51 (6H, m, C-2H₂ and C-3NCH₂), 3.59-3.82 (4H, m, C-3CH₂OH), 3.83 (2H, s, C-7CH), 4.87 and 5.03 (2H, ABq, J 15 Hz, C-3CH₂), 5.91 (1H, d, J 6 Hz, C-6H), 5.88 (1H, dd, J 6 and 9 Hz, C-7H), 6.93 (1H, s, C-4CH), 6.95-7.02 (3H, m, 2 thiophene and C-7NH) and 7.18-7.45 (11H, m, 10 phenyl and 1 thiophene H); MS (+ve FAB): m/z 652 (M+1).

Intermediate 5

Diphenylmethyl 3-(bis-2-methanesulphonylethylcarbamoyl)-7 β -(2-acetamido)-3-cephem-4-carboxylate

To a stirred solution of Intermediate 4 (0.19g) in pyridine (5ml) was added methanesulphonyl chloride (0.133g) dropwise. The mixture was stirred overnight at room temperature and then poured into saturated NaHCO₃ solution (100ml) and extracted twice with CH₂Cl₂ (100ml). The combined organic fractions were dried over MgSO₄, filtered and the solvent removed by evaporation in vacuo. The product was purified by column chromatography eluting with 25% ethyl acetate/CH₂Cl₂, to yield the title compound (0.076g), ¹H nmr_δH (CDCl₃): 2.95 (6H, s, OSO₂CH₃), 3.34-3.66 (6H, m, C-2H₂ and C-3NCH₂), 3.88 (2H, s, C-7CH₂), 4.15-4.40 (4H, m, C-3CH₂OMs), 4.80 and 5.12 (2H, ABq, J 15 Hz, C-3CH₂), 4.99 (1H, d, J 6 Hz, C-6H), 5.85 (1H, dd, J 6 and 8 Hz, C-7H), 6.73-7.02 (4H, m, C-4CH, C-7NH and 2 thiophene H) and 7.20-7.46 (11H, m, 1 thiophene and 10 phenyl H)

Intermediate 6

Diphenylmethyl 3-(bis-2-chloroethyl carbamoyl)-7 β -(2-acetamido)-3-cephem-4-carboxylate

To a stirred solution of N-chloro succinimide (0.267g) in dry tetrahydrofuran (20ml) under a nitrogen atmosphere at room temperature was added triphenyl phosphine (0.525g) as a solution in tetrahydrofuran (5ml). Upon formation of a white precipitate Intermediate 4 (0.65g) was added as a solution in tetrahydrofuran (5ml). The reaction mixture was stirred at room temperature until the precipitate had disappeared. The mixture was poured into NaHCO₃ solution and extracted twice with dichloromethane. The combined organic fractions were dried over anhydrous magnesium sulphate, filtered and the solvent removed by evaporation in vacuo. Purification was by flash column chromatography, eluting with 5% ethyl acetate/dichloromethane to yield the title compound, (0.6g) ¹H nmr_δH (CDCl₃): 3.26 and 3.47 (2H, ABq, J

18.5 Hz, C-2H₂) 3.42-3.70 (8H, m, ethyl H), 3.81 (2H, s, C-7CH₂), 4.82 and 5.13 (2H, ABq, J 12.5 Hz, C-3CH₂) 4.93 (1H, d, J 5.3 Hz, C-6H), 5.83 (1H, dd, J 5.3 and 8.6 Hz, C-7H), 6.86-7.08 (4H, m, C-4CH, C-7NH and 2 thiophene H) and 7.20-7.42 (11H, m, 1 thiophene and 10 phenyl H)

5

Intermediate 7

Diphenylmethyl 3-(bis-2-bromoethyl carbamoyl)-7β-(2-acetamido)-3-cephem-4-carboxylate

10

To a stirred solution of Intermediate 4 (0.35g) in dry pyridine (10ml) at room temperature under a nitrogen atmosphere was added dibromotriphenylphosphorane (0.5g) as a solid in a single portion. The reaction mixture was stirred for 2 hours at room temperature and then poured into saturated NaHCO₃ solution. The product was extracted twice with dichloromethane and the combined organic fractions dried over anhydrous magnesium sulphate, filtered and the solvent removed by evaporation in *vacuo*. Purification was by flash column chromatography, eluting with 10% ethyl acetate/dichloromethane to yield the title compound (0.1g). ¹H nmrδ_H (CDCl₃): 3.25-3.75 (10H, m, C-2H₂ and ethyl H), 3.82 (2H, s, C-7CH₂) 4.82 and 5.14 (2H, ABq, J 13 Hz, C-3CH₂), 4.94 (1H, d, J 6 Hz, C-6H) 5.85 (1H, dd, J 6 and 9 Hz, C-7H) 6.76 (1H, d, J 9 Hz, C-7NH), 6.93 (1H, s, C-4CH), 6.96-7.00 (2H, m, 2 thiophene H), and 7.17-7.45 (11H, m, 1 thiophene and 10 phenyl H)

20

Intermediate 8

25

Diphenylmethyl 3-(bis-2-hydroxypropyl carbamoyl)-7β-(2-acetamido)-3-cephem-4-carboxylate

The title compound was prepared from Intermediate 3 and diisopropanol amine in a similar manner to Intermediate 4. ¹H nmrδ_H (CDCl₃): 1.05-1.19 (6H, m, methyl H), 3.12-3.69 (8H, m, C-2H₂ and NCH₂CH), 3.79 (2H, s, C-7CH₂), 4.72-5.12 (3H, m, C-6H and C-3CH₂), 5.82 (1H, dd, J 6 and 10 Hz, C-7H), 6.86-7.94 (4H, m, C-4CH, C-7NH and 2 thiophene H) and 7.13-7.45 (11H, m, 1 thiophene and 10 phenyl H)

30

Intermediate 9

35

Diphenylmethyl 3-(bis-2-chloropropyl carbamoyl)-7β-(2-acetamido)-3-cephem-4-carboxylate

The title compound was prepared from Intermediate 8 in a similar manner to Intermediate 6. ¹H nmrδ_H (CDCl₃): 1.43 (3H, d, J 7 Hz, methyl), 1.51 (3H, d, J 7 Hz, methyl), 3.22-3.91 (8H, m, C-2H₂ and NCH₂CH), 3.83 (2H, s, C-7CH₂), 4.55-5.14 (2H, m, C-3CH₂) 4.98 (1H, d, J 6 Hz, C-6H) 5.84 (1H, dd J 6 and 8 Hz, C-7H), 6.85 (1H, d, J 8 Hz, C-7NH), 6.98-7.01 (3H, m, C-7NH and 2 thiophene H) and 7.32-7.47 (11H, m, thiophene and phenyl H).

40

Intermediate 10

Diphenylmethyl 3-(bis-2-bromopropyl carbamoyl)-7β-(2-acetamido)-3-cephem-4-carboxylate

50

The title compound was prepared in a similar manner to Intermediate 8 from Intermediate 8 and N-bromosuccinimide, ¹H nmrδ_H (CDCl₃): 1.48 (3H, d, J 7.5 Hz methyl H), 1.72 (3H, d, J 7.5 Hz methyl H), 3.23-3.95 (6H, m, C-2H₂ and NCH₂), 3.86 (2H, s, C-7CH₂), 4.34-4.48 (2H, m, CHBr), 4.70-5.22 (2H, m, C-3CH₂), 5.01 (1H, d, J 5 Hz, C-6H), 5.89 (1H, dd, J 5 and 8 Hz, C-7H), 6.32 (1H, d, J 8 Hz, C-7NH), 6.88-7.05 (3H, m, C-4CH and 2 thiophene H) and 7.26-7.48 (11H, m, thiophene and phenyl H).

55

Intermediate 11

Diphenylmethyl 3-(N,N bis(2-hydroxyethyl)-1,4-phenylenediamine carbamoyl-7 β -(2-acetamido)-3-cephem-4-carboxylate

The title compound was prepared from Intermediate 3 and N,N-bis(2-hydroxyethyl)-1,4-phenylenediamine, in a similar manner to Intermediate 4. ¹H nmr_{D₂O} (CDCl₃); 3.31-3.56 (6H, m, C-2H₂ and ArNCH₂), 3.73-3.85 (6H, m, C-7CH₂ and CH₂OH), 4.81 and 5.05 (2H, ABq, J 13 Hz, 3-CH₂), 4.91 (1H, d, J 5 Hz, C-6H), 5.82 (1H, dd, J 5 and 11 Hz, C-7H), and 6.57-7.46 (16H, m, C-7NH, NHAr, C-4CH, thiophene and phenyl H)

10

Intermediate 12Diphenylmethyl 3-(N,N bis (2-chloroethyl)-1,4-phenylenediamine carbamoyl-7 β -(2-acetamido)-3-cephem-4-carboxylate

The title compound was prepared from Intermediate 12 and dichlorotriphenylphosphorane, in a similar manner to Intermediate 7. ¹H nmr_{D₂O} (CDCl₃); 3.34-3.75 (10H, m, C-2H₂ and ethyl H), 3.87 (2H, s, C-7CH₂), 4.83-5.08 (2H ABq, J 13 Hz, C-3CH₂), 4.96 (1H, d, J 5 Hz, C-6H), 5.88 (1H, dd, J 5 and 10 Hz, C-7H), 6.85 (1H, d, J 10 Hz, C-7NH), 6.92-7.04 (3H, m, C-4CH and 2 thiophene H) and (11H, m, thiophene and phenyl H).

25

Intermediate 13Diphenylmethyl 3-chloromethyl-7 β -(2-thienylacetamido)-3-cephem-4-carboxylate

To a stirred solution of Intermediate 2 (5.35g) in dry tetrahydrofuran under a nitrogen atmosphere at 0 ° C was added pyridine (1.25ml) and dimethylformamide (10 μ l, catalysis). Thionyl chloride (1.126ml) was added dropwise and the mixture stirred for 10 minutes at 0 ° C. It was then poured into saturated NaHCO₃ solution and the product extracted twice with dichloromethane. The combined organic layers were dried over anhydrous magnesium sulphate, filtered and the solvent removed by evaporation in vacuo. Purification was by flash column chromatography, eluting with 10% ethyl acetate/dichloromethane to yield the title compound (1.59g) ¹H nmr_{D₂O} (CDCl₃); 3.43 and 3.59 (2H, ABq, J 18 Hz, C-2H₂), 3.86 (2H, s, C-7CH₂), 4.40 (2H, s, C-3CH₂), 4.98 (1H, d, J 5 Hz, C-6H), 5.85 (1H, dd, J 5 and 9 Hz, C-7H), 6.35 (1H, d, J 9 Hz, C-7NH), 6.93 (1H, s, C-4CH), 6.95-7.05 (2H, m, thiophene H), and 7.23-7.46 (11H, M, thiophene and phenyl H).

Intermediate 143-Chloromethyl-7 β -(2-thienylacetamido)-3-cephem-4-carboxylic acid

The title compound was prepared from Intermediate 13 in a similar manner to the compound of Example 1. ¹H nmr_{D₂O} (DMSO-d₆); 3.52 and 3.69 (2H, ABq, J 18 Hz, C-2CH₂), 3.82 (2H, s, C-7CH₂), 4.42 and 4.59 (2H, ABq, J 13 Hz, C-3CH₂), 5.07 (1H, d, J 5 Hz, C-6H), 5.82 (1H, dd, J 5 and 9 Hz, C-7H), 7.00-7.08 (2H, m, thiophene H), 7.32-7.40 (1H, m, thiophene H) and 9.12 (1H, d, J 9 Hz, C-7NH)

50

Intermediate 15Diphenylmethyl 3-fluoroacetoxymethyl-7 β -(2-thienylacetamido)-3-cephem -4-carboxylate

55

To a stirred solution of Intermediate 2 (1.42g) and pyridinium fluoroacetate (0.43g) in dry dichloromethane (5ml) at room temperature under a nitrogen atmosphere was added dicyclohexylcarbodiimide (0.564g). The reaction mixture was allowed to stir for 1 hour and then filtered, and the solvent removed by

evaporation in vacuo to yield the title compound (1.4g) which was used without further purification. ^1H nmr δ_{H} (CDCl_3): 3.37 (2H, d, J 4 Hz, C-3CH $_2$), 3.80 (2H, s, C-7CH $_2$), 4.70 (2H, d, J 48 Hz, CH $_2$ F), 4.97 (1H, d, 5 Hz, C-6H), 5.85 (1H, dd, J 5 and 12 Hz, C-7H), 6.91 (1H, s, C-4CH), 6.70-7.00 (3H, m, C-7NH and 2 thiophene H) and 7.10-7.60 (11H, m thiophene and phenyl H)

5

Intermediate 16

10 Diphenylmethyl 3-(2-chloroethyl carbamoyl)-7 β -(2 acetamido)-3-cephem-4-carboxylate

Intermediate 2 (0.97g) was dissolved in dry pyridine (10ml) at -23°C. To this was added 2-chloroethyl isocyanate (0.485ml) and the mixture stirred under nitrogen for 30 minutes after which the temperature was raised to room temperature and stirred for a further 4 hours. The pyridine was removed by evaporation in vacuo and the residue taken up in chloroform and washed with 1M HCl, saturated NaHCO $_3$ solution and water. The organic layer was dried with anhydrous magnesium sulphate, filtered and concentrated in vacuo. The product was purified by flash column chromatography eluting with 15% ethyl acetate/CH $_2$ Cl $_2$. The pure $\Delta 3$ isomer was isolated by crystallisation from ethyl acetate/petroleum ether to give the title compound (0.633g). ^1H nmr δ_{H} (CDCl_3): 3.32-3.59 (6H, m, C-2CH $_2$ and ethyl H), 3.86 (2H, s, C-7CH $_2$), 4.98 (1H, d, J 4.2 Hz, C-6H), 4.78 and 5.05 (2H, ABq, J 13.4 Hz, C-3CH $_2$), 5.88 (1H, dd, J 4.2 and 9.2 Hz, C-7H), 6.33 (1H, d, J 9.2 Hz, C-7NH), 6.95-7.03 (3H, m, C-4CH and thiophene H) and 7.27-7.45 (11H, m, thiophene and phenyl H).

25 Example 1

3-(Bis-2-methanesulphonylethyl carbamoyl)-7 β -(2-acetamido)-3-cephem-4-carboxylic acid

To a stirred solution of Intermediate 5 (0.076g) in CH $_2$ Cl $_2$ (10ml) at room temperature was added 0.5ml of anisole followed by 0.5ml of trifluoroacetic acid. The mixture was stirred for 2 hrs and then iPr $_2$ O (20ml) added and the solvent removed by evaporation in vacuo. Purification was by reverse phase HPLC eluting with 0.1% trifluoroacetic acid and 0.1% MeCN to yield the title compound (0.049g) ^1H nmr δ_{H} (CDCl_3): 3.08 (6H, s, OSO $_2$ CH $_3$), 3.42-3.70 (6H, m, C-2H $_2$ and C-3NCH $_2$), 3.79 (2H, s, C-7CH $_2$), 4.22-4.37 (4H, m, C-3CH $_2$ OMs), 4.80 and 5.07 (2H, ABq, J 12.9 Hz, C-3CH $_2$), 5.01 (1H, d, J 5.4 Hz, C-6H), 5.79 (1H, dd, J 5.4 and 8.8 Hz, C-7H), 6.92-7.00 (2H, m, 2 thiophene H) and 7.25-7.40 (2H, m, C-7NH and 1 thiophene H).

40 Example 2

3-(Bis-2-chloroethyl carbamoyl)-7 β -(2-acetamido)-3-cephem-4-carboxylic acid

The title compound was prepared in a similar manner to the compound of Example 1 from Intermediate 6. ^1H nmr δ_{H} (D_2O): 3.43-3.72 (10H, m, C-2H $_2$ and ethyl H), 3.82 (2H, s, C-7CH $_2$), 4.86 and 5.20 (2H, ABq, J 15 Hz, C-3CH $_2$), 5.08 (1H, d, J 6 Hz, C-6H), 5.73 (1H, d, J 6 Hz, C-7H), 6.92-7.00 (2H, m, thiophene H), 7.27 (1H, d, J 7 Hz, thiophene H) and 9.19 (1H, d, J 7.5 Hz, C-7NH).

50 Example 3

3-(Bis-2-bromoethyl carbamoyl)-7 β -(2-acetamido)-3-cephem-4-carboxylic acid

The title compound was prepared in a similar manner to the compound of Example 1 from Intermediate 7. ^1H nmr δ_{H} ($\text{DMSO}-d_6$): 3.25-3.75 (10H, m, C-2H $_2$ and ethyl H), 3.79 (2H, s, C-7CH $_2$), 4.71 and 5.06 (2H, ABq, J 13 Hz, C-3CH $_2$), 5.10 (1H, d, J 6 Hz, C-6H), 5.70 (1H, dd, J 6 and 9 Hz, C-7H), 6.90-7.00 (2H, m, 2 thiophene H), 7.37 (1H, d, J 5 Hz, thiophene H) and 9.15 (1H, d, J 9 Hz, C-7NH).

Example 43-(Bis-2-chloropropyl carbamoyl)-7 β -(2-acetamido)-3-cephem-4-carboxylic acid

The title compound was prepared from Intermediate 9 in a similar manner to the preparation of the compound of Example 1. ^1H nmr δ_{H} (D_3COD): 1.49 (6H, d, J 7.5 Hz, methyl), 3.47-3.78 (8H, m, C-2H₂ and NCH₂CH), 3.80 (2H, s, C-7CH₂), 4.82-5.21 (2H, m, C-3CH₂), 5.10 (1H, d, J 6 Hz, C-6H), 5.53 (1H, d, J 6 Hz, C-7H), 6.93-6.98 (2H, m, thiophene H), 7.28 (1H, d, J 7.5 Hz, thiophene) and 9.22 (1H, d, J 8Hz, C-7NH).

Example 53-(Bis-2-bromopropylcarbamoyl)-7 β -(2-acetamido)-3-cephem-4-carboxylic acid

The title compound was prepared in a similar manner to the compound of Example 1 from Intermediate 10. ^1H nmr δ_{H} (CD_3CN): 1.5 (6H, d, J 5 Hz, methyl H), 3.43-3.72 (6H, m, C-2H₂ and NCH₂), 3.82 (2H, s, C-7CH₂), 4.42-4.49 (2H, m, CHBr), 4.78-5.12 (2H, ABq, J 14 Hz, C-3CH₂), 5.04 (1H, d, J 4 Hz, C-6H), 5.78 (1H, dd, J 4 and 9 Hz, C-7H), 6.85-7.27 (3H, m, thiophene H) and 8.04 (1H, d, J 9 Hz, C-7NH).

Example 63-(N,N bis(2-chloroethyl)-1,4-phenylenediamine carbamoyl)-7 β -(2-acetamido)-3-cephem-4-carboxylic acid

The title compound was prepared in a similar manner to the compound of Example 1 from Intermediate 12. ^1H nmr δ_{H} (D_3COD): 3.52-3.73 (10H, m, C-2H₂ and ethyl H), 3.79 (2H, s, C-7CH₂), 4.72 and 5.06 (2H, ABq, J 14 Hz, C-3CH₂), 5.16 (1H, d, J 5 Hz, C-6H), 5.72 (1H, d, J 5 Hz, C-7H), 6.88 (2H, d, J 8 Hz, phenyl H), 6.93-6.99 (2H, m, thiophene H) and 7.25-7.34 (3H, m, thiophene and phenyl H).

Example 73-(Purin-6-ylthio methyl)-7 β -(2-acetamido)-3-cephem-4 carboxylic acid

To a stirred solution of Intermediate 4 (0.186 g) and 6-mercaptapurine (0.085g) in dry dimethylformamide (2ml) at room temperature was added 1,8-diazabicyclo[5.4.0]undec-7-ene (0.15ml). After 15 minutes the crude reaction mixture was purified by reverse phase HPLC eluting with 0.1% trifluoroacetic acid (TFA) $\text{H}_2\text{O}/0.1\%$ TFA/MeCN, to yield the title compound (0.8g) ^1H nmr δ_{H} ($\text{DMSO}-d_6$): 3.57 and 3.79 (2H, ABq, J 18 Hz, C-2H₂), 3.77 (2H, s, C-7CH₂), 4.11 and 4.90 (2H, ABq, J 13 Hz, C-3CH₂), 5.08 (1H, d, J 5 Hz, C-6H), 5.68 (1H, dd, J 5 and 9 Hz, C-7H), 6.90-6.97 (2H, m, thiophene H) 7.32 (1H, d, J 3 Hz, thiophene H), 8.42 (1H, s, purine H), 8.67 (1H, s, purine H) and 9.10 (1H, d, J 9 Hz, C-7NH).

Example 83-((5-Fluorouracil)methyl)-7 β -(2-acetamido)-3-cephem-4-carboxylic acid

The title compound was prepared in a similar manner to the compound of Example 7 from Intermediate 14 and 5-fluorouracil. ^1H nmr δ_{H} ($\text{DMSO}-d_6$): 3.41 and 3.53 (2H, ABq, J 18 Hz, C-2H₂), 3.78 (2H, s, C-7CH₂), 4.26 and 4.93 (2H, ABq, J 15 Hz, C-3CH₂), 5.07 (1H, d, J 4 Hz, C-6H), 5.61 (1H, dd, J 4 and 9 Hz, C-7H), 6.89-6.95 (2H, m, thiophene H), 7.34 (1H, d, J 3 Hz, thiophene H), 7.94 (1H, d, J 7.5 Hz, uracil H) and 9.13 (1H, d, J 9 Hz, C-7NH).

Example 93-(Guanin-6-ylthiomethyl)-7 β -(2-acetamido)-3-cephem-4-carboxylic acid

5 The title compound was prepared in a similar manner to the compound of Example 7 from Intermediate 14 and 6-thioguanine. ^1H nmr δ_{H} (DMSO- d_6): 3.52 and 3.63 (2H, ABq, J 18 Hz, C-2H $_2$), 3.64 (2H, s, C-7CH $_2$), 4.02 and 4.71 (2H, ABq, J 15 Hz, C-3CH $_2$), 5.10 (1H, d, J 5 Hz, C-6H), 5.65 (1H, dd, J 5 and 8 Hz, C-7H), 6.88-6.97 (2H, m, thiophene H), 7.30-7.38 (1H m, thiophene H), 7.95 (1H, s, guanine H) and 9.12 (1H, d, J 8 Hz, C-7NH).

Example 103-Fluoroacetoxymethyl-7 β -(2-thienylacetamido)-3-cephem-4-carboxylic acid

15 The title compound was prepared from Intermediate 15 in a similar manner to the compound of Example 1. ^1H nmr δ_{H} (DMSO- d_6): 3.51 and 3.62 (2H, ABq, J 18 Hz, C-2H $_2$), 3.77 (2H, s, C-7CH $_2$), 4.82 and 5.18 (2H, ABq, J 15 Hz, C-3CH $_2$), 5.04 (2H, d, J 37.5 Hz, CH $_2$ F), 5.10 (1H, d, J 5 Hz, C-6H), 5.72 (1H, dd, J 5 and 8 Hz, C-7H), 6.88-6.97 (2H, m, thiophene H), 7.47 (1H, d, J 4 Hz, thiophene H) and 9.14 (1H, d, J 8 Hz, C-7NH).

Example 113-(2-chloroethylcarbamoyl)-7 β -(2-acetamido)-3-cephem-4-carboxylic acid

25 The title compound was prepared in a similar manner to the compound of Example 1 from Intermediate 16. ^1H nmr δ_{H} (D $_3$ CN): 3.36-3.66 (6H, m, C-2H $_2$ and ethyl H), 3.78 (2H, s, C-7CH $_2$), 4.77 and 4.93 (2H ABq, J 14.4 Hz, C-3CH $_2$), 5.05 (1H, d, J 5.51 Hz, C-6H) 5.75 (1H, dd, J 5.1 and 8.9 Hz, C-7H), 6.00 (1H, s, C-3NH), 6.92-7.01 (2H, m, thiophene H) and 7.24-7.36 (2H, m, C-7NH and thiophene H).

Example 123-(2-chloroethyl N-nitroso carbamoyl)-7 β -(2-acetamido)-3-cephem-4-carboxylic acid

40 A slurry of anhydrous sodium acetate (0.579g) in dry dichloromethane (5ml) was cooled to -78°C. NO $_2$ was bubbled through dichloromethane (10ml) to give a solution of N $_2$ O $_4$ (1.31g). This was added to the sodium acetate slurry.

The compound of Example 11 (0.315g) was suspended in dichloromethane (15ml) and was dissolved by addition trifluoroacetic acid (0.3ml). The resulting solution was cooled to 0°C and added dropwise to the solution N $_2$ O $_4$. After 15 minutes the reaction mixture was warmed to -23°C and stirred for a further 20 minutes. The solvent was removed by evaporation in vacuo and the residue triturated with isopropyl ether. The residue was taken up in chloroform, washed with brine, dried with anhydrous magnesium sulphate and concentrated in vacuo. The product was purified by reverse phase HPLC, eluting with 0.1% trifluoroacetic acid TFA.acetonitrile, to yield the title compound. ^1H nmr δ_{H} (CD $_3$ CN): 3.56 (2H, t, ethyl H), 3.54 and 3.71 (2Hm ABQ, J 17.3 Hz, C-2H $_2$), 3.78 (2H, s, C-7CH $_2$), 4.06 (2H, t, ethyl H), 5.07 (1H, d, J 5.1 Hz, C-6H), 5.17 and 5.47 (2H ABq, J 13.3 Hz, C-3CH $_2$), 5.79 (1H, dd, J 5.1 and 9.2 Hz, C-7H) 6.94-7.01 (2H, m, thiophene H) and 7.27-7.34 (2H, m, C-7NH and thiophene H).

Example 13

β -Lactamase Catalysed Cleavage of Prodrug of Drug

The ability of various β -lactamases to catalyse the hydrolysis of the prodrugs prepared in the above Examples was tested.

- 5 Purified β -lactamases from several microorganisms were tested namely: *Enterobacter cloacae* p99, *E.coli* RTEM; *Bacillus cereus* I and II; and *Staphylococcus aureus*.

The method used was as follows:

- Each prodrug (0.05ml of a 10mM solution in 50mM phosphate buffer, pH7.0) was mixed with phosphate buffer (0.95ml; 50mM; pH7.0) and the solution scanned using a UV-VIS spectrophotometer in the wavelength range 200-500nm. β -Lactamase (0.01ml of a 1 mg.ml⁻¹ solution in 50mM phosphate buffer, pH7.0) was mixed with the solution, which was then incubated at 37°C, and scanned, as previously, at 5 minute intervals.

- In addition, 6-mercaptopurine and 6-thioguanine prodrug (Example 7 and 9) hydrolysis could be followed by an increase in absorbance at 323 and 340nm respectively. In the case of the 5-fluorouracil prodrug (Example 8) the spectrum of the drug portion, 5-fluorouracil, interfered with the change in absorbance of the β -lactam ring. Cleavage of the β -lactam ring was therefore followed by use of a stopped assay which detects the cephalosporic acid by reaction with copper sulphate and neocuproine as follows:

10 μ l 50 μ M-1mM prodrug in DMSO

10 μ l β -Lactamase

- 20 80 μ l 50mM phosphate buffer pH7.0

were incubated at 37°C for 30 min

400 μ l 50mM phosphate buffer pH7.0

500 μ l solution C (equal volumes of solutions A and B, see below)

were then added. After 2 hrs, the absorbance of the solutions at 450nm was determined.

- 25 [Solution A: 16mg neocuproine - HCl in 1.2 ml H₂O + 18.8 ml 0.2M Na acetate pH4.75 + 10g/l sodium dodecyl sulphate (SDS)

Solution B: 40mg CuSO₄ · 5H₂O in 20ml 0.2M sodium acetate pH4.75 + 10 g/l SDS

Solution C: equal volumes of A and B]

- Evidence for release of the drug from the prodrug was obtained by following the enzyme/prodrug reaction by NMR and comparing the spectrum of the product formed with the known spectrum of the prodrug. In the case of the 6-mercaptopurine and 6-thioguanine prodrugs this was unnecessary as the UV-VIS spectra of the drugs are distinctive and identical to the reaction products.

- Rates of hydrolysis were determined in the case of the mustard prodrugs (Examples 2,3,4 and 5) by following the decrease in absorbance at 265nm with time after addition of 0.1-10 μ g/ml β -Lactamase to 0.1mg/ml prodrug in buffer

35 6-mercaptopurine was followed at 323nm

6-thioguanine was followed at 340 nm

The rate of hydrolysis of selected prodrug by β -lactamase is give below in Table 1.

Table 1

Enzyme Source	Prodrug - Compound of Example No.	kcat/Km (M ⁻¹ s ⁻¹)	kcat (s ⁻¹)	Km (μ M)
E.cloacae	2	4.7 x 10 ⁶	515	109
	3	2.1 x 10 ⁶	151	73
	5	3.0 x 10 ⁶	120	40
E.coli	4	1.5 x 10 ⁵	10.5	70
	7	5.9 x 10 ⁴	8.1	138
B.cereus II	4	6.3 x 10 ⁴	3.4	54
	3	5.5 x 10 ⁴	3.5	63

- In each instance cleavage of the β -Lactam ring was observed, with release of the drug from the prodrug.

Example 14

Preparation of a chemically cross-linked B72.3- β lactamase conjugate

(a) Derivatisation of Antibody: Reaction of antibody lysine residues with 2-iminothiolane.

5

Monoclonal antibody B72.3 [Colcher, D. et al Proc. Nat. Acad. Sci. USA (1981), 78, 3199; 1ml of a 6mg.ml⁻¹ solution in 0.1M sodium bicarbonate buffer, pH8.3] was mixed with 2 iminothiolane [0.1ml of a 1mg.ml⁻¹ solution in 0.1M sodium bicarbonate buffer, pH8.3] and the reaction mixture left to stand at room temperature for 30 minutes. Excess 2-iminothiolane was separated from thiolated antibody by gel filtration on a PD10 column (in 0.1M sodium acetate/sodium citrate buffer, pH6.0 containing 2mM EDTA), the thiolated antibody was collected and concentrated to 4.26mg.ml⁻¹.

10

(b) Derivatisation of Enzymes: Reaction with succinimide ester

15

3-Maleimidobenzoyl-N-hydroxysuccinimide ester (0.39 mg) in dimethylformamide (0.039ml) was added to β -lactamase (B-cereus I; 0.25 ml of a 10mg.ml⁻¹ solution of enzyme in H₂O) and the mixture allowed to react at room temperature for 45 minutes with gentle stirring. Excess unreacted succinimide ester was separated by gel filtration on a PD10 column (in 0.1M sodium acetate - sodium citrate buffer, pH6.0), the substituted β -lactamase was collected and concentrated to 4.5mg.ml⁻¹.

20

(c) Preparation of conjugate

25

The substituted β -lactamase (2mg) prepared in Part (b) was added to the thiolated antibody (1 mg) prepared in Part (a) and the mixture left overnight with constant stirring. B72.3 - β -lactamase conjugate was then separated from the mixture using hplc gel filtration on a Dupont GF-250 column (retention time of product = 7.21 minutes; unreacted thiolated antibody = 8.18 minutes; unreacted β -lactamase = 11.7 minutes). The B72.3- β -lactamase product was characterised on the basis of its β -lactamase activity (assessed using 10⁻⁴M cephaloridine in 50mM sodium phosphate, pH7.0 and monitoring change in absorbance at 254) and its immunoreactivity (assessed using an enzyme linked immunoabsorbent assay employing a TAG antigen). Both β -lactamase activity and antigen binding activity were retained in the conjugate.

30

Incubation of the antibody- β -lactamase conjugate with the compound of Example 16 using the methods described in Example 13 resulted in cleavage of the β -lactam ring and release of the drug from the prodrug.

35

Example 15

40

Antibody- β -lactamase hybrid Proteins produced by Recombinant DNA technology

Antibody enzyme hybrids may be produced by recombinant DNA means whereby the DNA encoding at least the antigen recognition elements of an antibody is fused to that of the DNA encoding at least the active portion of an enzyme. This DNA sequence together with that of the complementary light or heavy chain of the antibody is then expressed in E.coli, yeast or mammalian cells using appropriate expression vectors and the antibody-enzyme hybrid produced purified and characterised by the standard techniques of protein biochemistry and immunology.

45

In order to produce a hybrid suitable for the demonstration of the principle of antibody directed cleavage of a prodrug, DNA encoding for the heavy chain CHI and hinge region of the antibody anti NP (nitro iodophenyl antigen) was fused to DNA encoding the entire β -lactamase gene. This was expressed (together with the corresponding light chain gene) using an appropriate vector in a transient expressing mammalian COS cell system. The resulting protein produced was shown to consist of the assembled light and heavy chain- β -lactamase fusion. The anti NP- β -lactamase enzyme hybrid was further shown to be capable of both recognising the specific hapten nitroiodophenol and exhibiting β -lactamase activity.

50

The anti-NP β -lactamase hybrid protein was produced as follows

(1) Construction of COS cell Expression Vector

Plasmid EE7.H3 [International Patent Application No. PCT/GB89/00614] was restricted with HindIII and SmaI and then treated with alkaline phosphatase.

5 PSV.VnG 2b Δ(CH2, CH3), a known plasmid having an operon encoding the heavy chain variable domain, first constant domain and hinge region of an anti-NP (nitroiodophenyl) antigen, was digested with XhoI and incubated with T4 DNA polymerase to fill in the XhoI site. After removal of the T4 DNA polymerase activity, the DNA was restricted with HindIII and the largest fragment [HindIII-Xho(blunt)] of coding sequence for the first constant domain and hinge region of the antibody was inserted between the
10 HindIII and SmaI site of the restricted and treated EE7.H3 plasmid. This produced the plasmid EE7.CH1H and recreated a unique XhoI site.

PSV.VnG 2b Δ(CH2, CH3) was also digested with NcoI and the synthetic oligonucleotide 5' CATGGTGGAAGCTTCCAC3' was ligated thereto. This reformed the NcoI site with Kozak consensus sequence (CCACC) around the initiator ATG and placed a HindIII site upstream. Digestion of the ligation
15 product with HindIII allowed the isolation of a HindIII fragment containing the variable domain of NP gene (Approx. 1100bp). This HindIII fragment was cloned into the HindIII site of EE7.CH1H to produce the plasmid EE7.VCH1H.

Into this vector was cloned the K2SP domain from TPA as described in International Patent Specification No. WO89/12098. This generated the plasmid termed EE7.VCH1H.K2SP. The HCMV promoter was
20 isolated on a 2.1kb HindIII fragment from EE6.HCMV (International Patent Specification No. 89/01036) and cloned into EE7.VCH1H.K2SP that had been partially digested with HindIII. A plasmid was isolated that contained the HCMV fragment in the correct orientation and upstream of the V region of the anti-NP gene. This plasmid is EE7.VCH1H.K2SP.HCMV. This plasmid was used to construct the β-lactamase anti-NP fusion by exchanging the K2SP fragment, which could be isolated on a XhoI fragment.

25

Construction of a suitable β-lactamase gene to clone into EE7.VCH1H.K2SP.HCMV

A commercially available plasmid [hereinafter termed pPOD2352] containing most of the E.coli RTEM
30 β-lactamase gene was obtained. The 5' sequence was as follows:

R1

5' AAGCTTGAATCGAATTCAGCTTGCCCCCAGAAACG

35

P A C P P E T

The sequence AATT is the recognition sequence for the restriction enzyme EcoRI

40 The region underlined is the N terminal amino acid sequence of the mature processed β-lactamase starting at residue 2. The correct N terminal sequence for β-lactamase is given below:
H P E T L....

In order to clone this gene three different modifications had to be performed.

- a) An XhoI site was added to the 5' end of the gene
- b) The DNA sequence coding for the N terminal His was added to the gene pPOD2353
- 45 c) An XhoI site was added to the 3' end of the gene

The above manipulations were performed using appropriate synthetic oligonucleotides as primers for the polymerase chain reaction (PCR). The sequence for the forward oligonucleotide in the PCR is
5' GGGGGCTCGAGCACCCAGAAACGCTGGTGAAA 3'

50 The above oligo nucleotide places a XhoI site immediately upstream of the first codon of the fully processed β-lactamase gene, such that the sequence through the junction will be -CH2/β-lac:
.....NLEHPETL.....

The sequence NLE is the C terminal sequence of the CH2 domain of the anti-NP antibody, and the remaining sequence is the N terminal sequence of β-lactamase.

Th sequence for the "reverse" oligonucleotide in the PCR is:
55 5' GGGGGCTCGAGTTTAAATCAATCTAAAGTAT 3'

The above oligonucleotide places a XhoI site downstream from the natural stop codon from β-lactamase from plasmid pPOD2353.

The product from the PCR was restricted with XhoI and this fragment was purified using standard

protocols.

The plasmid EE7.VCH1H.K2SP.HCMV was restricted with XhoI which resulted in the loss of the K2SP gene and the plasmid treated with alkaline phosphatase. Into this vector was cloned the β -lactamase XhoI cut PCR product (described above). A plasmid (pNPSTCH) was isolated that contained the β -lactamase fragment in the correct orientation.

(2) Expression of pNPSTCH

The plasmid pNPSTCH was expressed in a transient expression system involving transfection into COS-1 cells. COS-1 cells are derived from CV1 monkey kidney cells (Gluzman, 1981) which have been transfected with the SV40 virus with its origin of replication deleted. The COS-cell transfection procedure provides a rapid, and easily reproducible method for producing, analytical quantities of protein for biochemical characterisation [Whittle et al (1987), Protein Engineering, 1, 499-505] Biosynthetic radio-labelling of transfected cells, followed by purification and visualisation by SDS PAGE can demonstrate that the gene product is correctly transcribed and translated to generate a polypeptide of the expected size.

The plasmid pNPSTCH was co-transfected, with a plasmid containing the anti-NP light chain gene (pNPLC), into COS-1 cells. Following incubation at 37°C for 72h the cell supernatants were assayed for β -lactamase activity. Determination of enzyme activity of the β -lactamase constructs was performed by addition of cell supernatant to 1mM cephalothin in 50mM phosphate buffer pH7, and following the decrease in absorbance at 265nm. Quantification was performed by determining the rates of hydrolysis by known concentrations of *E.coli* RTEM β -lactamase in the same medium.

A blank assay (containing no cell supernatant) and a control supernatant from COS cells transformed with a plasmid encoding a NP fusion with a portion of the tPA enzyme (termed aNIPK2sp) showed essentially no β -lactamase activity. However, a supernatant from COS cells transformed with PNPSTCH and PNPCLC showed β -lactamase activity (equivalent to approximately 0.1 μ g/ml enzyme).

The ability of the NP- β -lactamase fusion to bind NP antigen was analysed. Expressed COS cell proteins were labelled for 48h following transfection, with [³⁵S]methionine (Whittle et al, 1987 *ibid*) Supernatants from the COS cells were incubated overnight with Sepharose beads coupled to NP. After washing the beads, bound proteins were separated on an SDS-10% PAGE under reducing and non-reducing conditions. The gel was treated with an autoradiography enhancer (Amplify, Amersham International) dried and exposed to X-ray sensitive film. The molecular weights of the various fragments which might be generated are given below

- β -lactamase (approx 30K)
- Light chain (approx 28K)
- Fd + hinge (approx 30K)
- Fd + hinge + β -lactamase (approx 60K)

If correct expression is taking place then the predicted distribution of bands from samples analysed under reducing conditions are, free light chain (30K), and a band of 60K which corresponds to the heavy chain with β -lactamase attached. The samples treated under non-reducing conditions are expected to give two different species:

(1) F(ab)₂-like molecules with 2 molecules of β -lactamase attached

(2) Fab molecules with β -lactamase attached. From the result obtained it was clear that the transformed COS-1 cells were producing molecules which were capable of binding to NP, and that all of the species which were predicted above to be made from the genes were present.

A formal possibility remains that the β -lactamase activity observed in the COS supernatants is from free β -lactamase arising from enzymatic cleavage from the antibody and that the measured pro-drug activity is from free β -lactamase.

In order to demonstrate that the activity observed in the pro-drug assay was due to β -lactamase attached to antibody, an assay was performed in which 2 identical COS cell supernatants expressing NP- β -lactamase were treated as detailed below:

To one of the samples NP-sepharose was added and left incubating at room temperature. The second sample was incubated without NP sepharose at room temperature. Both samples were then centrifuged and identical volumes removed and assayed for pro-drug activation. It was observed that incubation of COS cell supernatants with NP sepharose depleted β -lactamase activity thus demonstrating the fusion of antigen binding and β -lactamase activities.

Example 16Cell tissue culture assay of relation drug/pr drug toxicity

5 A tissue culture assay using a mouse lymphoma cell line [Phillips (1974), Biochem. Pharmacol. 23, 131-138] was used to determine the relative toxicity of drug and prodrug samples. The cephalosporin - prodrugs tested were those of Example 2,5,6 - 10 and 12.

For compounds of Examples 2, and 7-10 the corresponding non-cephalosporin linked drug was tested.
 10 In the case of compounds of Examples 5, 6 and 12 the drug portion of the prodrug was generated in situ in the assay by the addition of the enzyme β -lactamase as indicated below.

Methodology

15

(i) Cell line

Mouse lymphoma cells, line L5178Y clone 3.7.2.C, was used for these studies. This clone was derived
 20 from the L5178Y wild-type line and is heterozygous for the thymidine kinase locus. It is widely used for assays of mutation of thymidine analogue resistance (loss of thymidine kinase). Stocks were maintained frozen in liquid nitrogen and recovered 7 days before the start of the study.

25 (ii) Culture conditions

The cells were grown in RPMI 1640 medium buffered with 25 mM HEPES, and supplemented with 10% horse serum, 1mM sodium pyruvate, and 0.05% Pluriol (PF 6800 from BASF). In most cases, penicillin (100 iu/ml) and streptomycin (100µg/ml) were also included in the medium. Stock cultures were maintained by
 30 subculture into fresh medium every 2-3 days. Incubation was at 37°C in an atmosphere of 5% CO₂ in air. Under these conditions, the cells grew as a static cell suspension with a population doubling time (cell cycle time) of 10-12 hr.

35 (iii) Cytotoxicity assay

A growing culture, at a cell density of $1-2 \times 10^5$ /ml, was diluted with fresh medium to a density of 5×10^4 cells/ml. An appropriate number of universal bottles was prepared with 4.5ml medium and 0.5ml cell suspension to give a final cell concentration of 5×10^4 cells/ml. In some tests, the cells were centrifuged
 40 and resuspended in Hank's Balanced Salt Solution (HBSS) to allow treatment in a simpler medium.

Test solutions were added in dimethylsulphoxide DMSO (final concentration 0.5% for continuous exposure or 1% for 1 hr exposure) and controls received the same amount of DMSO. Where applicable, β -lactamase was added (50µl of a 1mg/ml solution in phosphate buffered saline).

For 1 hr exposure of the cells, the universal bottles were incubated on a rotary mixer (2 revs per min) at
 45 37°C for 1 hr and the medium changed to remove the test compound. In other cases, the treated cell suspensions were plated out immediately. At least 4 wells (15mm diameter) of Nunclon^R 24-well plastic multidishes were inoculated with 1ml each from each universal bottle. The plates were incubated at 37°C.

The cell number per well at the start of incubation was checked by pooling the remaining suspension from each universal and counting a sample with a Coulter^R electronic particle counter. Counts were made
 50 on two wells per treatment after incubation of the plates for 24, 48 or 72 hr. The contents of each well were mixed thoroughly with a Pasteur pipette to break up cell clumps and diluted 1 in 10 before counting twice with the Coulter counter.

55 (iv) Calculation of ID₅₀

Cell growth was expressed as the number of population doublings (PD) achieved during a given time period (t hrs), calculated as follows:

$$\text{Log (mean count at t hrs + mean count at 0 hrs)}$$

$$\text{PD} = \frac{\text{Log (mean count at t hrs + mean count at 0 hrs)}}{\text{Log 2}}$$

$$\text{Log 2}$$
(v) Calculations

Growth relative to control (% G) was calculated for each treatment as follows:

$$\% G = \frac{\text{PD (Treated)}}{\text{PD (Control)}} \times 100$$

 β -Lactamase

A 1mg/ml stock solution of β -lactamase (RTEM) was prepared in 50mM phosphate buffer pH7 containing 0.2% azide. For assays of drug toxicity β -lactamase at a final concentration of 10mg/ml was utilised. At this concentration there was complete conversion of prodrug to drug within 5 minutes.

RESULTS

Differential toxicity between prodrug and drug (assayed as described above) were up to 13 fold with ID_{50} s in the micro molar range. Typical results, from the cephalosporin-thioguanine prodrug [compound of Example 9] drug system, are given below in Table 2.

Table 2

<u>Compound</u>	<u>M_r</u>	<u>ID₅₀</u> μ (M)	<u>Differential</u> <u>Toxicity</u> (ID ₅₀ Prodrug/drug)
(i) Cephalosporin - thioguanine (Prodrug)	504	6.44)))	13
(ii) Thi guanine (drug)	167	0.53))	

This demonstrates a clear differential toxicity between prodrug and drug in this cephalosporin - thioguanine (Prodrug) /thioguanine (drug system), which was also observed in the other prodrug/drug

systems tested in this Example.


The results thus demonstrate the suppression of the characteristic toxicity of each drug when incorporated in the prodrug structure.

5

Claims


1. A system for delivering a drug at a host target site, the system comprising an immunoconjugate and a prodrug for use in association with each other, said immunoconjugate being capable of recognising and binding to one or more epitopes associated with the host target site and having a β -lactamase action capable of hydrolysing said prodrug to active drug or an unstable precursor thereof at the target site, characterised in that said prodrug comprises a cyclic amide derivative of a drug or an unstable precursor thereof wherein the drug or unstable precursor thereof is linked to the remainder of the prodrug such that it forms a leaving group which on hydrolysis of the prodrug is eliminated as the active drug or an unstable precursor thereof.

2. A system according to Claim 1 wherein the prodrug is a cephalosporin or penicillin derivative of formula (3)



wherein R is an acyl or alkyl radical; R¹ is a hydrogen atom or an alkoxy group; B is -CH₂-, -O-, or -S-, n is zero or an integer 1 to 4 inclusive and L is a drug or an unstable precursor thereof linked to the remainder of the molecule such that it forms a leaving group.

3. A system according to Claim 1 or 2 wherein the prodrug is a monobactam of formula (4)



wherein R is an acyl or alkyl radical; R¹ is a hydrogen atom or an alkoxy group and L is a drug or an unstable precursor thereof linked to the remainder of the molecule such that it forms a leaving group.

4. A system according to Claims 2 or 3 wherein L in formulae (3) and (4) is linked to the remainder of the molecule through an oxygen, nitrogen or sulphur atom present in the drug or unstable precursor.

5. A system according to Claim 4 wherein L in formulae (3) and (4) is a group -O-CO-L¹ or -S-L¹ where L¹ is the remainder of the drug or an unstable precursor.

6. A system according to any of the preceding claims wherein the host target site is a tumour, and the


prodrug comprises a cyclic amide derivative of an antineoplastic agent or an unstable precursor thereof.

7. A system according to any of the preceding claims wherein the immunoconjugate is a whole antibody or an antigen binding fragment thereof covalently linked to a β -lactamase enzyme or an active fragment thereof.

8. A system according to Claim 7 wherein the β -lactamase enzyme or active fragment thereof is from *Escherichia*, *Staphylococci*, *Pseudomonas*, *Bacteriodes*, *Klebsiella*, *Citrobacter*, *Bacillus*, *Enterobacter* or *Streptococci*.

9. A system according to Claim 8 wherein the β -lactamase enzyme or active fragment thereof is from *B.cereus*, *Enterobacter cloacae* or *E.coli*.

10. A compound of formula (3)



wherein R is an acyl or alkyl radical, R¹ is a hydrogen atom or an alkoxy group; B is -CH₂-, -O- or -S-; n is zero or an integer 1 to 4 inclusive and L is an antineoplastic agent or an unstable precursor thereof linked to the remainder of the molecule such that it forms a leaving group.

11. A compound as claimed in Claim 10 wherein B is -S- and n is an integer 1.

12. A compound as claimed in Claim 11 wherein R¹ is a hydrogen atom.

13. A compound according to Claims 10 - 12 wherein the antineoplastic agent, L, is an alkylating agent; an antimetabolite; an antibiotic; a mitotic inhibitor; an alkaloid; a hormone; a urea; a hydrazine; or an imidazole.

14. A compound according to Claims 10-13 wherein the antineoplastic agent L is linked to the rest of the molecule through an oxygen, nitrogen or sulphur atom present in L.

15. A compound as claimed in Claim 14 wherein the antineoplastic agent L is -O-CO-L¹ or -S-L¹ where L¹ is the remainder of the antineoplastic agent or an unstable precursor thereof.

16. A compound as claimed in Claim 15 wherein the antineoplastic agent L is a group -O-CO-L¹ and L¹ is a group -NR⁶R⁷ wherein R⁶ and R⁷ are the same or different and is each a hydrogen atom or an optionally substituted C₁₋₆ alkyl group with the proviso that only one of R⁶ and R⁷ is a hydrogen atom; or L¹ is a group -P-NR⁶R⁷ where P is a phenyl group.


17. A compound as claimed in Claim 15 wherein L is a mercaptopurine or thioguanine group.

18. A compound as claimed in any of Claims 10-17 wherein R is an optionally substituted aliphatic, heteroaliphatic, aromatic, heteroaromatic, araliphatic or heteroaraliphatic carboxylic or carbothioic acid radical or a carbamoyl radical.

19. A compound as claimed in Claim 18 wherein R is a group R²C=X where X is an oxygen or sulphur atom and R² represents a hydrogen atom or an optionally substituted group selected from amino, substituted amino, C₁₋₆alkyl, C₁₋₆arylthio, C₆₋₁₂arylthio, C₁₋₆alkoxy, C₆₋₁₂aryloxy, C₂₋₆alkenyl or alkynyl, aryl, arC₁₋₃alkyl, C₃₋₆cycloalkyl, C₄₋₁₀heteroaryl or heteroarC₁₋₃alkyl.

20. A compound as claimed in Claim 19 wherein R is 2-thienylacetyl.

21. A compound of formula (5)



15 wherein W is a group -OCOOW' and W' is a fluorophenyl group

22. A compound according to Claim 21 wherein W' is a pentafluorophenyl group.

20

25

30

35

40

45

50

55